|
|
||||||||
Pulmonary and Critical Care Division, Departments of Medicine, Physiology, Pathology, and Pharmacology, University of South Alabama College of Medicine, Mobile, Alabama 36688
| |
ABSTRACT |
|---|
|
|
|---|
The adenosine
agonist
5-(N-ethylcarboxamido)adenosine (NECA)
induces vasodilation in the pulmonary circulation via
A2-adenosine-receptor activation.
We addressed whether prolonged treatment with NECA desensitizes in
A2-adenosine- receptor function in
isolated lung and pulmonary artery smooth muscle cells (PASMC). In lung
microcirculation preconstricted with a hypoxic gas, initial
administration of NECA caused a 57% vasodilatory response after
3-4 min. Readministration of NECA after 45 min resulted in minimal
vasodilation. The highest accumulation of PASMC cAMP occurred 3-5
min after NECA, coincident with NECA-induced vasodilation. In PASMCs
treated with NECA for 45 min, cAMP did not increase. Isoproterenol- and
indolidan-induced vasodilation remained intact in NECA-desensitized
lungs. In NECA-desensitized PASMCs, isoproterenol-induced cAMP
accumulation was decreased, suggesting a common mechanism of
desensitization. cAMP accumulation was decreased in cholera
toxin-treated NECA-desensitized PASMCs compared with cholera
toxin-treated control PASMCs, demonstrating that
Gs
-adenylyl cyclase signaling
contributes to desensitization. The
A2a-adenosine-receptor agonist
CGS-21680C neither increased cAMP accumulation in PASMCs nor attenuated
NECA-induced vasodilation. These data support that the
A2b-adenosine receptor is
responsible for pulmonary vasodilation and desensitization through
mechanisms(s) involving
Gs
-adenylyl cyclase signaling.
Gs
-adenylyl cyclase
signaling; adenosine 3',5'-cyclic monophosphate; pulmonary
artery vasodilation
| |
INTRODUCTION |
|---|
|
|
|---|
CENTRAL VENOUS INFUSION of adenosine (Ado) reduces pulmonary vascular resistance when administered over a short period (~15 min) in cardiac surgical patients without pulmonary hypertension (4). This vasodilation is selective for the pulmonary circulation without affecting systemic vascular resistance or mean systemic arterial pressure. Lack of an effect on the systemic circulation with central venous infusion of Ado reflects its rapid clearance from blood by adenosine deaminase found in vascular endothelial cells and red blood cells (13, 20). Because of this short half-life (4, 13, 18) and rapid clearance from the pulmonary circulation, Ado is a potential agent that can be administered locally in the pulmonary circulation without having undesired systemic effects.
A problem with the clinical utility of Ado is its potential to produce
A2-adenosine-receptor
desensitization after sustained infusion. Although desensitization of
the A2-adenosine receptor has not
been demonstrated in the pulmonary circulation, the downregulation of
Gs
protein, inhibition of
adenylyl cyclase, and activation of phosphodiesterase have been
observed in other cell lines as mechanisms of
A2-adenosine-receptor
desensitization (2, 11, 12). We therefore sought to determine whether
prolonged administration of Ado agonists results in sustained
vasodilation or receptor desensitization in the pulmonary circulation.
On the basis of previous observations (3, 8, 16, 19, 25) in the
precontracted pulmonary vascular bed, Ado-mediated vasodilation occurs
after activation of the A2-
adenosine receptor, probably of the
A2b subtype (8), which is coupled
through a Gs
protein to
adenylyl cyclase activation (19, 27, 28). Adenylyl cyclase activation
increases intracellular cAMP and mediates vasodilation (25). In this
study we investigate effect(s) of prolonged
A2-adenosine-receptor exposure to
the nonmetabolizable nonselective Ado agonist
5-(N-ethylcarboxamido)adenosine (NECA) and the selective
A2a-adenosine-receptor agonist
CGS-21680C on Ado-mediated vasodilation in the lung and on cAMP
accumulation in pulmonary artery smooth muscle cell (PASMC) cultures
from the Sprague-Dawley rat.
| |
METHODS |
|---|
|
|
|---|
Materials. Ado, NECA, ANG II, and isoproterenol (Iso) were purchased from Sigma Chemical (St. Louis, MO). CGS-21680C was a kind gift from Ciba-Geigy (Summit, NJ), and indolidan (Ind) was a kind gift from Lilly Research Laboratories (Indianapolis, IN). All drugs were solubilized in normal saline except for NECA and CGS-21680C, which were dissolved in distilled H2O, and Ind, which was dissolved in DMSO.
Isolated perfused lung. Male
Sprague-Dawley rats (270-340 g) were anesthetized with Nembutal
sodium (25 mg ip), and lungs were removed for extracorporeal perfusion
as previously described (6, 17). A tracheostomy was performed that
permitted ventilation with a Harvard rodent ventilator (model 683) at
55 breaths/min with a tidal volume of 2.5 ml and 2.0 cmH2O positive end-expiratory pressure. The inspired gas mixture was 95% air-5%
CO2 (room air gas). During hypoxic
challenges, lungs were ventilated with a 3%
O2-5%
CO2-balance
N2 (hypoxic gas) gas mixture. A
median sternotomy was performed, heparin sodium (100 IU) was injected
in the right ventricle, and cannulas were placed in the pulmonary
artery and left ventricle. Heart, lungs, and mediastinal structures
were removed en bloc and placed into a humidified chamber. Lungs were perfused by a Gilson Minipuls 2 peristaltic pump at a constant flow of
0.03 ml · g body
wt
1 · min
1.
Lungs were perfused with homologous blood (30 ml) previously collected
in a heparinized syringe by cardiac puncture from three or four adult
male Sprague-Dawley rats anesthetized with Nembutal sodium. The
temperature of the recirculating blood was maintained at 37°C.
Pulmonary arterial (Ppa) and
venous pressures were continuously monitored with Cope pressure
transducers (041-500-503) and were recorded on a Grass
polygraph recorder (model 7E).
After a 30-min equilibration period, all lungs were challenged with 0.1 g ANG II injected as a bolus in the pulmonary artery. Ten minutes after
the ANG II challenge, lungs were ventilated with the hypoxic gas
mixture for 10 min, and the first hypoxic pressor response (HPR1) was
assessed. Room air gas was reinstituted, and lungs were allowed to
equilibrate for 10 min (Table 1). This was
followed by two 25-min sequential hypoxic challenges (HPR2, HPR3,
n = 16 each). At the peak (~10 min)
of HPR2, NECA (10 µM, final perfusate concentration) was administered
to the reservoir, and the change in
Ppa was monitored for an
additional 15 min. At the peak of HPR3, NECA (10 µM) was administered
(total of 20 µM NECA in perfusate) and
Ppa was again monitored for 15 min
(group A). With the use of the identical
protocol, five lungs previously exposed to 20 µM NECA were washed
with 100 ml of a 4 g/100 g albumin-physiological salt solution and
reperfused with fresh homologous blood (30 ml) in a recirculating
fashion as described above (group B). After a
10-min equilibration period, lungs were subjected to a fourth hypoxic
challenge (HPR4). At the peak of HPR4, NECA (10 µM, final perfusate
concentration) was administered to the reservoir, and the decrease in
Ppa was compared with the decrease
in Ppa observed after NECA
administration during the peak of HPR2.
|
In group A, 11 lungs that demonstrated an attenuation of NECA-mediated vasodilation were subjected to HPR4, and either Ado (7.5 mM, n = 4), the nonselective agonist, Iso (1 µM, n = 3), or the cGMP-inhibitable cAMP phosphodiesterase inhibitor (7) Ind (1 µM, n = 4) was administered, and any change in Ppa was observed over a 15-min period (Table 1). In control lungs that were subjected to four sequential hypoxic challenges and not administered NECA (group C), studies were performed with Ado (7.5 mM, n = 3), Iso (1 µM, n = 3), and Ind (1 µM, n = 3) administration during the plateau of HPR4 for comparison with NECA-pretreated lungs from group A that were administered either Ado, Iso, or Ind. Whereas Iso and Ind were administered in the perfusate reservoir, Ado was infused in the pulmonary artery at a rate 0.125 ml/min.
In the final group of lungs, the selective A2a-adenosine- receptor agonist CGS-21680C was added to the perfusate in a concentration of either 10 µM (n = 4, group F) or 1,000 µM (n = 4, group G) during HPR2 (45 min before 10 µM NECA administration). NECA was administered at the peak of the HPR3 as described above, and any change in Ppa was observed over 15 min. This change in Ppa seen with NECA was compared with that seen with NECA administration during HPR2 and HPR3 in group A.
PASMC. Main pulmonary arteries were
isolated from anesthetized rats, and ~2-mm-large tissue fragments
were placed immediately in 1:1 F-12 nutrient mixture and DMEM mixture
supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 0.1 mg/ml streptomycin (GIBCO-BRL Products, Grand Island, NY). After 3 days
under standard incubation conditions the tissue pieces were removed,
and cells that had migrated from the explants were grown to confluency. Culture medium was changed every 3 days. Cells from passages 4-8 were harvested using a 0.05% solution of trypsin (GIBCO) and were seeded in 24-well plates (Costar, Cambridge, MA) with 1 × 105 cells in 2 ml of medium per
well. The plates were used for experiments after 3-4 days when the
cells reached confluency. Smooth muscle cell phenotype was confirmed by
the presence of smooth muscle-specific
-actin as detected by
fluorescein-labeled specific antibodies (Sigma). Cell counts were
determined by particle counter (Coulter Electronics, Luton, UK).
Measurement of cAMP content. Assessment of cAMP content was performed using standard RIA (Biomedical Technologies, Stoughton, MA). After PASMC were grown to confluency as described above, experiments were conducted using DMEM, with pH balanced to 7.4 and osmolality equal to 285-305 mosmol/kgH2O. Agonists were added for the time periods indicated, cells were washed with DMEM, and cells were solubilized (reactions stopped) using 1 M NaOH. After assessment of cAMP concentrations, results were standardized to cell counts (106 cells).
Statistics. Results are presented as means ± SE. Statistical analyses were performed using the paired and unpaired Student's t-test and one-way ANOVA. Tukey's test (29) was used for multiple comparisons when ANOVA indicated statistically significant differences between groups. Differences were considered significant at P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
Isolated lung. Initial studies were
designed to assess whether prolonged Ado receptor activation results in
desensitization of the
A2-adenosine receptor. In
group A, HPR2 and HPR3 were 22.3 ± 1 and 20.8 ± 1 cmH2O,
respectively. The administration of NECA (10 µM) during HPR2 resulted
in a 12.7 ± 0.7 cmH2O decrease
in Ppa below the peak HPR2 at
2-4 min and an 8.7 ± 1 cmH2O decrease in
Ppa at 15 min. In contrast to the
initial 57% vasodilatory response with NECA, repeat administration of
NECA resulted in a 0.6 ± 0.3 cmH2O decrease in
Ppa at 2-4 min and a 2.4 ± 0.4 cmH2O increase in
Ppa above the initial peak
Ppa at 15 min (Fig.
1).
|
In lungs from group B, repeat administration of NECA (10 µM) during HPR4 decreased the peak Ppa by only 3.9 ± 1.3 cmH2O at 2-4 min and by 1.7 ± 2.2 cmH2O at 15 min. This NECA response was significantly diminished (P < 0.05) compared with the decrease in Ppa observed during HPR2, which was 9.9 ± 1.3 cmH2O at 2-4 min and 8.2 ± 1.2 cmH2O at 15 min. Repeat administration of NECA in lungs from groups A and B resulted in an attenuation of NECA-induced vasodilation and is consistent with desensitization of the A2-adenosine receptor.
In group A where NECA-induced
vasodilation could no longer be demonstrated, Ado, Iso, and Ind were
administered (Fig. 2). Similar to NECA, Ado
decreased Ppa 1.3 ± 1.4 cmH2O compared with the 15.4 ± 1.5 cmH2O decrease in
Ppa observed in
group C (no NECA pretreatment).
Administration of Iso and Ind to lungs that were pretreated with NECA
and refractory to NECA-induced vasodilation resulted in an attenuation
of HPR4 comparable to that observed in lungs not previously treated
with NECA (Table 2).
|
|
To assess whether the A2a-adenosine receptor was involved in Ado receptor desensitization, lungs were pretreated with the selective A2a-adenosine-receptor agonist CGS-21680C (10 and 1,000 µM) during HPR2 and allowed to recirculate ~45 min before NECA administration. CGS-21680C (10 µM) did not mediate a vasodilatory response when administered at the peak of HPR2. In contrast, CGS-21680C (1,000 µM) caused a 32 ± 3% decrease in HPR2. Unlike the relatively complete desensitization observed in group A with sequential NECA administration, NECA resulted in a 13.6 ± 2.2 cmH2O decrease in Ppa in lungs pretreated with CGS-21680C (10 µM), which was not significantly different from the 12.7 ± 0.7 cmH2O decrease observed with HPR2 in group A. However, in lungs pretreated with CGS-21680C (1,000 µM) the decrease in Ppa seen with NECA was 2.6 ± 0.5 cmH2O, which was significantly less than seen with HPR2 in group A and similar to the attenuation of NECA-mediated vasodilation observed with HPR3 in group A.
PASMC culture. To confirm whether NECA
and CGS-21680C activation of the
A2-adenosine receptor increased
cAMP, PASMC cultures were exposed to either NECA (10 µM), CGS-21680C
(10 µM), or vehicle over a 45-min time course (Fig.
3). Activation of the
A2-adenosine receptor by NECA
increased cAMP 876% above control at 5 min. After 45 min of
NECA, PASMC cAMP accumulation decreased to 169% of control. In
contrast, activation of the
A2a-adenosine receptor with
CGS-21680C produced no detectable increase in cAMP, indicating
that activation of the
A2b-adenosine receptor most likely
accounted for NECA-induced increases in cAMP.
|
In the isolated lung, an ~45-min exposure to NECA desensitized the
pulmonary circulation to subsequent NECA-induced vasodilatory challenges. We next examined whether PASMC were similarly desensitized to NECA-induced cAMP production. To test this idea, PASMC were exposed
to either vehicle or NECA (10 µM) for 45 min (as in Fig. 2) and
subsequently rechallenged with either vehicle, NECA (10 µM), Iso (1 µM), or Ind (1 µM) for 3 min. Whereas vehicle pretreatment followed
by application of NECA increased cAMP 239% above control, NECA
pretreatment followed by application of NECA did not significantly increase cAMP content (Fig. 4). These data
are consistent with desensitization of the NECA-induced cAMP signaling
pathway observed in the pulmonary circulation.
|
Interestingly, in PASMC culture, 45-min exposure to NECA
significantly attenuated responsiveness to
-adrenergic
stimulation with Iso. Whereas vehicle pretreatment followed by
application of Iso elicited a 340% increase in cAMP above control,
NECA pretreatment followed by Iso produced a 234% increase in cAMP
(Fig. 5). In contrast, NECA pretreatment
did not influence cAMP responsiveness to Ind (Fig. 5).
|
We examined whether NECA desensitization of cAMP stimulation involved G
protein activation by pretreating PASMC with either vehicle or NECA (10 µM) for 45 min followed by stimulation of Gs
proteins using cholera toxin
(10
10 to
10
8 M). NECA pretreatment
attenuated responsiveness to cholera toxin 312%, consistent with
desensitization of Gs
proteins
for activation of adenylyl cyclase (Fig.
6).
|
| |
DISCUSSION |
|---|
|
|
|---|
The purpose of this study was to investigate whether desensitization of the A2-adenosine receptor occurs in the rat pulmonary circulation on prolonged exposure to the synthetic nonmetabolizable Ado agonist NECA. We found that sequential administration of NECA (10 µM each dose) in the isolated rat lung precontracted with hypoxic gas caused an acute vasodilatory response with a maximum decrease in Ppa 3-4 min after administration. However, ~45 min after the initial administration, repeat administration of NECA resulted in only a minimal vasodilatory response. This effect of NECA in the lung closely paralleled cAMP accumulation in PASMC culture. In PASMCs, the highest accumulation of cAMP occurred ~3-5 min after NECA administration, coincident with the vasodilatory response in isolated perfused lungs. Furthermore, in PASMCs pretreated with NECA for 45 min, washed, and rechallenged with NECA, no increase in cAMP was observed. These findings demonstrate that Ado receptor desensitization occurs, likely due to reduced activation of the Ado receptor-coupled Gs-adenylyl cyclase stimulation of cAMP.
NECA-induced desensitization was not limited to the Ado receptor. In
PASMC culture treated with NECA for 45 min followed by Iso, cAMP
accumulation was significantly reduced compared with PASMCs treated
with Iso alone. A plausible explanation for the observed decrease in
cAMP accumulation in NECA-desensitized PASMCs treated with Iso is
2-adrenergic receptor
phosphorylation by protein kinase A (PKA; see Ref. 5). NECA-stimulated
increase in cAMP production acutely activates PKA, which phosphorylates the
2-adrenergic receptor and
uncouples the receptor from Gs
protein. PKA activation by NECA-generated increases in intracellular cAMP may be the mechanism responsible for
2-adrenergic receptor phosphorylation and desensitization in this study. Penn et al. (21)
have recently reported that agents which stimulate cAMP production such
as forskolin and PGE2 activate
PKA, which results in
2-adrenergic receptor
desensitization in human airway smooth muscle cell culture. This cannot
be excluded as a possible mechanism for the observed decrease in cAMP
accumulation with Iso in PASMC culture. Data derived from
NECA-desensitized PASMCs treated with cholera toxin (irreversibly
couples the A2 adenosine receptor to Gs
) revealed a decrease in
stimulation of cAMP accumulation when compared with cAMP accumulation
in PASMCs treated with cholera toxin alone. This observation coupled
with the decreased cAMP accumulation after Iso in NECA-desensitized
PASMCs suggests that a common mechanism of desensitization is likely
that involves Gs-adenylyl cyclase
signaling. Potential mechanisms of
Gs
involvement may include
dissociation of ligand-receptor complex from
Gs
, impaired
Gs
binding to and activation of
adenylyl cyclase, and downregulation of
Gs
. Downregulation of
Gs
protein as a mechanism of
A2a-adenosine-receptor
desensitization has been described in rat pheochromocytoma PC-12 cells
when exposed to the selective A2a-adenosine agonist CGS-21680
for 12-20 h (2).
Desensitization of the
A2-adenosine receptor has been
characterized in smooth muscle of porcine coronary artery ring (15), dithiothreitol, MF-2 cells (22), and rat pheochromocytoma PC-12 cells
(2, 14). To date, studies characterizing
A2-adenosine-receptor desensitization have evaluated the
A2a-adenosine receptor (2, 14,
22). There is a paucity of studies characterizing
A2b-adenosine-receptor desensitization. Reported mechanisms of
A2a-adenosine
receptor-desensitization include inhibition of adenylyl cyclase,
downregulation of Gs protein, and
activation of phosphodiesterase. Interestingly, no studies demonstrate
desensitization due to a change in receptor number or affinity. Common
to all the reported studies,
A2-adenosine-receptor desensitization occurs rapidly. Makujina and Mustafa (15)
demonstrated that NECA and CGS-21680 caused rapid desensitization of
A2-adenosine-receptor-mediated vasodilation in precontracted porcine coronary artery rings. Tissues pretreated with NECA for 30 min exhibited a blunted relaxation response
to Ado and NECA but not to other vasodilators such as Iso, forskolin,
and sodium nitropusside (15). This led to the conclusion that, in
porcine coronary artery smooth muscle,
A2-adenosine-receptor desensitization is homologous. Similar observations were made in the
isolated lung in this study, suggesting a homologous pattern of rapid
desensitization to NECA manifested by blunted NECA-induced vasodilation
while maintaining Iso and Ind vasodilation in NECA-desensitized lungs.
Despite evidence in the pulmonary circulation that prolonged exposure
to NECA functionally induces homologous desensitization, data from in
vitro studies indicated that NECA desensitization of PASMCs was
heterologous. Prolonged NECA exposure eliminated NECA-induced increases
in cAMP and also diminished Iso-stimulated rises in cAMP. Why the
patterns of desensitization differed between PASMC culture and isolated
lung cannot be answered from this study but suggest Iso-induced
vasodilation is mediated only in part via
Gs
-adenyl cyclase-cAMP
signaling. We could speculate that the preservation of Iso-induced
vasodilation in the lung reflects the capacity of the many different
cells to make cAMP. Although this is true,
vasodilation is a reflection of cAMP accumulation in smooth muscle
cells and not the amount of cAMP in the circulation. The most plausible
explanation for the reported differences observed in this study is
perhaps related to the modulation of vascular smooth muscle
K+ channels by Ado and
-adrenoreceptor agonists. Several investigators (24, 26) have
reported that Ado, calcitonin gene-related peptide, and
-adrenoreceptor agonists activate the ATP-sensitive
K+ channel through a
cAMP-dependent protein kinase, which results in vasodilation. In
addition, Iso has been shown to also activate the
Ca2+-activated
K+ channels
(BKCa) through
Gs
independent of
phosphorylation by PKA (23). It is possible that vasodilation in the
isolated lung was preserved through activation of the
BKCa and explains why Iso-induced
cAMP accumulation in NECA-desensitized PASMC culture was blunted while
Iso-induced vasodilation was preserved. Further studies will be
necessary to address this question.
Because the A2-adenosine receptor has two subtypes, A2a and A2b, their relative individual roles in desensitization were assessed. NECA binds the A2a receptor with high affinity and the A2b receptor with low affinity (1, 9, 11). The concentration of NECA utilized in this study exceeds the previously reported dissociation constant for NECA binding to the low-affinity A2b-adenosine receptor in rat striatum (286 nM; see Ref. 9) and human peripheral lung (200 nM; see Ref. 11). Thus it could not be used to distinguish which A2-adenosine-receptor subtype(s) is involved in the process of Ado agonist desensitization. CGS-21680 is now the current ligand of choice for the characterization of the high-affinity A2a receptor (10). In this study, pretreatment with CGS-21680C (10 µM) neither caused desensitization to NECA-induced vasodilation in the isolated lung nor caused a significant accumulation of cAMP in PASMC culture. We previously reported (8) that pretreatment with CGS-21680C (1 mM) was required to significantly promote desensitization to NECA-induced vasodilation in the isolated lung. The requirement of a millimolar concentration of CGS-21680C to desensitize the lung to NECA and its lack of effect at a micromolor concentration on cAMP accumulation in PASMC culture strongly supports that the low-affinity A2b receptor is the predominant receptor involved in Ado-mediated vasodilation and subsequent desensitization in the rat pulmonary circulation. This differs from the observation in the porcine coronary artery ring where a desensitization to CGS-21680 parallels that observed with NECA (15). This difference in response to CGS-21680 suggests that the presence of the A2a-adenosine receptor may either be species specific and/or vary according to the vascular bed studied, i.e., pulmonary vs. coronary. Using immunohistochemical staining, we have been able to demonstrate the presence of both the A2a- adenosine receptor and A2b-adenosine receptor in rat pulmonary vascular beds (data not shown).
In summary, this study demonstrates that the
A2b- adenosine receptor is
involved in Ado-mediated vasodilation through increasing intracellular
cAMP and that relatively prolonged agonist exposure results in
desensitization via Gs
-adenylyl
cyclase coupling. The findings in this study provide a functional model
for expanding our understanding of the various effects of Ado on
pulmonary vascular hemodynamics and desensitization.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Sandy Mead for the preparation of this manuscript. Also, many thanks go to Aubrey E. Taylor, Joseph Thompson, and Jim Downey for the review of this manuscript.
| |
FOOTNOTES |
|---|
This work was supported by the Florence Foundation Research Career Development Grant and the Comprehensive Sickle Cell Program Grant P60 HL-38639 from the National Heart, Lung, and Blood Institute.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests: J. Haynes, Univ. of South Alabama, Medical Center, 2451 Fillingim St., 10th Fl., Suite H, Mobile, AL 36617.
Received 24 September 1998; accepted in final form 3 February 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Bruns, R. F.,
G. H. Lu,
and
T. A. Pugsley.
Characterization of A2-adenosine receptor by [3H]NECA in rat striatal membranes.
Mol. Pharmacol.
29:
331-346,
1986[Abstract].
2.
Chern, Y.,
H.-L. Lai,
J. C. Fong,
and
Y. Liang.
Multiple mechanisms for desensitization of A2a-adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells.
Mol. Pharmacol.
44:
950-958,
1993[Abstract].
3.
Cutaia, M.,
and
S. Rounds.
Hypoxic pulmonary vasoconstriction.
Chest
97:
706-718,
1990
4.
Fullerton, D. A.,
L. E. Kirson,
S. D. Jones,
and
R. C. McIntyre.
Adenosine is a selective pulmonary vasodilator in cardiac surgical patients.
Chest
109:
41-46,
1996
5.
Hausdorff, W. P.,
M. G. Caron,
and
R. J. Lefkowitz.
Turning off the signal: desensitization of
-adrenergic receptor function.
FASEB J.
4:
2881-2889,
1990[Abstract].
6.
Haynes, J.,
D. W. Killiea,
P. D. Peterson,
and
J. Thompson.
Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3',5'-guanosine monophophate-stimulated phospho-diesterase to reverse hypoxic pulmonary asoconstriction in the perfused rat lung.
J. Pharmacol. Exp. Ther.
276:
752-757,
1996
7.
Haynes, J.,
P. A. Kithas,
A. E. Taylor,
and
S. J. Strada.
Selective inhibition of cGMP-inhibitable cAMP phosphodiesterase decreases pulmonary vasoreactivity.
Am. J. Physiol.
261 (Heart Circ. Physiol. 30):
H487-H492,
1991
8.
Haynes, J.,
B. Obiako,
J. Thompson,
and
J. Downey.
Adenosine-induced vasodilation: receptor characterization in pulmonary circulation.
Am. J. Physiol.
268 (Heart Circ. Physiol. 37):
H1862-H1868,
1995
9.
Hide, I.,
W. L. Padgett,
K. A. Jacobson,
and
J. W. Daly.
A2a adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase.
Mol. Pharmacol.
41:
352-359,
1992[Abstract].
10.
Jarvis, M. F.,
R. Schulz,
A. F. Hutchinson,
U. H. Do,
M. A. Sills,
and
M. Williams.
[3H]CGS 21680, a selective A2-adenosine receptor agonist directly labels A2 receptors in rat brain.
J. Pharmacol. Exp. Ther.
251:
888-893,
1989
11.
Joad, J. P.,
and
K. S. Kott.
Effect of adenosine receptor ligands on cAMP content in human airways and peripheral lung.
Am. J. Respir. Cell Mol. Biol.
9:
134-140,
1993.
12.
Keen, M.,
E. Kelley,
A. Krane,
A. Austin,
R. Wittshire,
N. Taylor,
K. Docherty,
and
J. MacDermot.
Cyclic AMP produces desensitization of prostacyclin and adenosine A2 receptors in hybrid cell lines but does not affect GS function.
Biochim. Biophys. Acta
1134:
157-163,
1992[Medline].
13.
Klabunde, R. E.
Dipyridamole inhibition of adenosine metabolism in human blood.
Eur. J. Pharmacol.
93:
21-26,
1983[Medline].
14.
Lai, H.-L.,
T.-H. Yang,
R. O. Messing,
V.-H. Ching,
S.-C. Lin,
and
Y. Chern.
Protein kinase C inhibits adenylyl cyclase type VI activity during desensitization of A2a-adenosine receptor-mediated cAMP response.
J. Biol. Chem.
272:
4970-4977,
1997
15.
Makujina, S. R.,
and
S. J. Mustafa.
Adenosine-5'-uronamides rapidly desensitize the adenosine A2 receptor in coronary artery.
J. Cardiovasc. Physiol.
22:
506-509,
1993.
16.
McCormack, D. G.,
B. Clark,
and
P. J. Barnes.
Characterization of adenosine receptors in human pulmonary arteries.
Am. J. Physiol.
256 (Heart Circ. Physiol. 25):
H41-H46,
1989
17.
McMurtry, I. F.,
A. B. Davidson,
J. T. Reeves,
and
R. T. Grover.
Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonist in isolated rat lungs.
Circ. Res.
38:
99-104,
1976
18.
Parsons, W. J.,
and
G. L. Stiles.
Heterologous desensitization of the inhibitory A1-adenosine receptor-adenylate cyclase system in rat adipocytes.
J. Biol. Chem.
262:
841-847,
1987
19.
Pearl, R. G.
Adenosine produces pulmonary vasodilation in the perfused rabbit lung via an adenosine A2 receptor.
Anesth. Analg.
79:
46-51,
1994
20.
Pearson, J. D.,
S. Carleton,
A. Hutchings,
and
J. L. Gordon.
Uptake and metabolism of adenosine by pig aortic endothelial and smooth-muscle cell in culture.
Biochem. J.
170:
265-271,
1978[Medline].
21.
Penn, R. B.,
R. A. Panettieri, Jr.,
and
J. L. Benovic.
Mechanisms of acute desensitization of the
2AR-adenylyl cyclase pathway in human airway smooth muscle.
Am. J. Respir. Cell Mol. Biol.
19:
338-348,
1998
22.
Ramkumar, V.,
M. E. Olan,
K. A. Jacobson,
and
G. L. Stiles.
Distinct pathways of desensitization of A1-and A2-adenosine receptors in DDT1 MF-2 cells.
Mol. Pharmacol.
40:
639-647,
1991[Abstract].
23.
Scornik, F. S.,
J. Codina,
L. Birnbaumer,
and
L. Toro.
Modulation of coronary smooth muscle KCa channels by Gs independent of phosphorylation by protein kinase A.
Am. J. Physiol.
265 (Heart Circ. Physiol. 34):
H1460-H1465,
1993
24.
Sheridan, B. C.,
R. C. McIntyre, Jr.,
and
D. R. Meldrum.
KATP channels contribute to
- and adenosine receptor-mediated pulmonary vasorelaxation.
Am. J. Physiol.
273 (Lung Cell. Mol. Physiol. 17):
L950-L956,
1997
25.
Silver, P. J.,
K. Walus,
and
J. Disalvo.
Adenosine-mediated relaxation and activation of cyclic AMP-dependent protein kinase in coronary arterial smooth muscle.
J. Pharmacol. Exp. Ther.
228:
342-347,
1984
26.
Standen, N. B.,
and
J. M. Quayle.
K+ channel modulation in arterial smooth muscle.
Acta Physiol. Scand.
164:
540-557,
1998.
27.
Steinberg, T. H.
Adenosine and adenosine receptors.
Am. J. Respir. Cell Mol. Biol.
2:
127-128,
1990.
28.
Tucker, A. L.,
and
J. Linden.
Cloned receptors and cardiovascular responses to adenosine.
Cardiovasc. Res.
27:
62-67,
1993
29.
Zar, J. H.
Statistical Analysis. Englewood Cliffs, NJ: Prentice-Hall, 1974, p. 153.
This article has been cited by other articles:
![]() |
B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, K.-N. Klotz, and J. Linden International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors Pharmacol. Rev., December 1, 2001; 53(4): 527 - 552. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Sitaraman, M. Si-Tahar, D. Merlin, G. R. Strohmeier, and J. L. Madara Polarity of A2b adenosine receptor expression determines characteristics of receptor desensitization Am J Physiol Cell Physiol, June 1, 2000; 278(6): C1230 - C1236. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-L. Matharu, S. J. Mundell, J. L. Benovic, and E. Kelly Rapid Agonist-induced Desensitization and Internalization of the A2B Adenosine Receptor Is Mediated by a Serine Residue Close to the COOH Terminus J. Biol. Chem., August 3, 2001; 276(32): 30199 - 30207. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |